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I
n the November issue of PLoS 
Medicine, Auvert and colleagues 
report the ﬁ  rst randomised 
controlled trial of circumcision for 
preventing HIV infection [1]. In the 
study, 3,274 uncircumcised men, 
aged 18–24 years, were randomised 
to a control or intervention group, 
with follow-up at three, 12, and 21 
months. Circumcision was offered to 
the intervention group immediately 
after randomisation and to the control 
group at the end of the follow-up (only 
men who wished to be circumcised 
were eligible for the trial). There were 
20 HIV infections in the intervention 
group and 49 in the control group, 
corresponding to a relative risk 
of 0.40 (95% conﬁ  dence interval, 
0.24–0.68; p < 0.001). The relative risk 
was unchanged when controlled for 
behavioural factors, including sexual 
behaviour, condom use, and health-
seeking behaviour, suggesting that 
male circumcision provides a degree 
of protection against acquiring HIV 
infection.
Prior to conducting the study, the 
study proposal (protocol study number 
M020104) was reviewed in January 
2002 by the Human Research Ethics 
Committee (Medical), which is the 
institutional review board (IRB) of 
the University of the Witwatersrand in 
Johannesburg, South Africa, and which 
I chair. The committee decided to 
approve the study, and in this article I 
discuss how we came to our decision.  
Background to the Committee
The committee was formed in October 
1966 soon after the seminal paper by 
Beecher on ethics and clinical research 
was published [2]. It has functioned 
continuously, ever since, according to 
local [3] and international [4] research 
ethics guidelines. The committee has 
United States federal-wide accreditation 
(FWA 0000715), and is one of the few 
IRBs outside the US that has had a site 
quality assurance visit by a team from 
the US Ofﬁ  ce of Human Research 
Protections (the visit was in 2002, 
headed by Deputy Director Melody 
Lin). 
At the time when we reviewed Auvert 
and colleagues’ protocol, there were 27 
members, 12 women and 15 men, from 
diverse ethnic backgrounds. Twenty-
four members were from the University 
of the Witwatersrand, of whom 16 had 
medical or scientiﬁ  c expertise and 
eight had nonmedical backgrounds in 
law, social work, ethics, and psychology. 
There were three independent 
members (with backgrounds in 
education, nursing, and religion). 
Seven members of the committee 
had, or were obtaining, postgraduate 
qualiﬁ  cations in applied ethics up to 
doctoral level. Over half the members 
had at least ten years of experience—
the maximum was 28 years—and three 
members served, or had served, on the 
IRBs of the Medical Research Council 
and Human Sciences Research Council 
in South Africa. All but three were born 
in South Africa.
Importance of the Study
There were four reasons why the 
committee believed that the proposed 
study had local importance, and that 
it should be conducted urgently. 
First, the proposal dealt with a serious 
infection with a seroprevalence in 2002 
of 26.5% among pregnant women, 
according to a national government 
survey [5]. 
Second, in 2002, government 
policy concerning HIV was to provide 
condoms, safe-sex counselling, 
and voluntary HIV testing after 
counselling—but no antiretroviral 
treatment to those infected. Such 
treatment was only available from 
government health centres, starting in 
2004 [6]. In other words, at the time 
when we considered the study protocol, 
the public-sector standard of care did 
not include antiretroviral medication. 
Third, anecdotal evidence at the 
time when we considered this proposal 
suggested that circumcision might 
be protective against heterosexual 
acquisition of HIV in men, but ﬁ  rm 
evidence was lacking. A year later, 
a meta-analysis of published studies 
concluded that while epidemiological 
evidence was supportive, the outcome 
of randomised controlled trials would 
be important in determining the value 
of circumcision [7]. 
Finally, in many African cultures in 
South Africa, initiation into manhood 
is accompanied by circumcision 
performed by a “traditional surgeon”. 
In recent times, because of high 
mortality from haemorrhage, 
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infections, and dehydration [8], many 
African men now opt for circumcision 
in adult life by a medical practitioner.
Ethical Considerations
We were, therefore, convinced that 
the study was important, and we then 
went on to consider whether it would 
be ethical. There were four guiding 
principles in our ethical deliberations.
Autonomy. Autonomy was respected 
through a written informed-consent 
process, with verbal translation into 
vernacular if needed. This process 
also fulﬁ  lled a local legal requirement, 
since informed consent to participate 
in research is entrenched in the 
Bill of Rights of the South African 
Constitution [9]. No false promises 
were made that might have inﬂ  uenced 
a person’s decision to participate.
Beneﬁ  cence. All participants would 
receive their desired circumcision. 
They would also have repeated medical 
examinations and counselling at 
each follow-up visit. Such counselling 
involved education about safe-sex 
practices and the beneﬁ  ts of being 
tested for HIV. Participants who wished 
to know their HIV status were referred 
for an HIV test. 
One criticism that has been 
levelled at studies of HIV in South 
Africa is that not all participants are 
routinely informed of their HIV status. 
Our committee understands the 
stigmatisation faced by people in South 
Africa who are HIV positive [10], and 
so we accepted the right of individuals 
in the study to choose whether or 
not to be tested, once they had been 
counselled. 
If during the study a participant 
became infected with syphilis, or any 
other sexually transmitted disease 
for which treatment was provided 
at government health centres, the 
participant would be referred to 
the nearby health centre to receive 
treatment. 
Beneﬁ  cence was also allowed for 
through scheduled interim analyses, 
with results provided to a three-person 
data safety and monitoring board 
in order to stop the study as soon as 
statistically signiﬁ  cant results had been 
found (see below). 
Non-maleﬁ  cence. The study’s 
proposed participants were to be only 
those who wished to be circumcised. All 
participants would receive their desired 
procedure, half immediately and half 
at the end of the study, so there would 
be no withholding of the operation. A 
potential source of disadvantage would 
be if there was a selection process 
before enrolment, for example, testing 
for HIV and accepting only people who 
were HIV negative into the study. The 
researchers had anticipated this, and all 
who wished to enrol were accepted—
adjustment for HIV status at enrolment 
was through a large sample size and 
statistical analysis. 
A second concern of the researchers 
was that the results of the tests for 
HIV and herpes simplex virus should 
not be known by the researchers 
in order to keep them “blinded” 
and, hence, minimise bias. Because 
voluntary testing for these viruses 
was offered at each follow-up, the 
researchers’ concern was accepted by 
the committee. 
No treatment would be provided for 
HIV or herpes simplex virus infection, 
according to government policy. The 
Declaration of Helsinki recommends 
provision of treatment for a disease 
being studied, and so our committee 
debated at length the issue of whether 
the researchers had an ethical duty 
to provide treatment. We concluded, 
as put forward by Benatar [11], that 
a moral judgment had to be made 
considering local conditions, the short 
period of the study (which was less than 
the 5–7 years considered appropriate 
at the time to reach a clinical need 
for antiretroviral treatment), and the 
ﬁ  nances involved. In 2002, the South 
African government was not offering 
treatment for these two infections, and 
so we agreed that it would be ethical 
for no treatment to be provided to the 
study’s participants.
Justice. Justice was adhered to by 
ensuring that the potential participants 
were recruited from disadvantaged 
groups who might not have had ready 
access to medical circumcision.
Interim Analyses
The ﬁ  rst interim analysis showed no 
statistically signiﬁ  cant effect. The 
second, at 12 months, did show such 
an effect, and so the data safety and 
monitoring board recommended 
that the study be stopped—and the 
committee agreed. At this stage, the 
researchers amended the study to 
allow HIV, herpes simplex virus, and 
syphilis results recorded in the study 
to be given to those participants, after 
counselling and informed consent, who 
had not previously wished to know.
By then the government policy had 
changed to providing antiretroviral 
therapy. The researchers undertook to 
do their best to provide HIV treatment 
for up to ﬁ  ve years to those participants 
for whom such treatment was clinically 
indicated, and the committee approved 
this course of action. 
Conclusion
This randomised trial presented a 
challenge to the IRB to combine 
general principles of research ethics 
with local conditions to permit a 
very important study to be done. 
Functioning, as the IRB does, in a 
developing country environment 
requires knowledge of local cultures, 
resources, and services. This is not 
always understood nor accepted by 
IRBs and researchers who operate in 
resource-rich environments. The fact 
that circumcision is so clearly protective 
should beneﬁ  t many men, particularly 
those in countries with a high HIV 
prevalence.  
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